Tumor Treating Fields and Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma: A Secondary Analysis of a Randomized Clinical Trial

Importance: The PANOVA-3 trial demonstrated the survival benefit and tolerability of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel, but understanding the impact of TTFields therapy on quality of life (QoL) and pain is important for clinical decision-making. Objective: To analyze the impact of TTFields therapy concomitant with gemcitabine and nab-paclitaxel on QoL and pain outcomes using prospective data from PANOVA-3. Design, Setting, and Participants: This is a prespecified secondary analysis of PANOVA-3, which was a global, open-label, multicenter, phase 3 randomized clinical trial in adult patients with previously untreated locally advanced unresectable pancreatic adenocarcinoma (LA-PAC). A total of 571 patients were randomized between May 1, 2018, and March 31, 2023, with follow-up completed October 31, 2024. Data analysis was performed from November 2024 to May 2025. Intervention: Patients were randomized 1:1 to receive either TTFields therapy (150 kHz) with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. Nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) were administered intravenously on days 1, 8, and 15 of 28-day cycles. Duration of follow-up was 18 months. Main Outcomes and Measures: QoL was measured using the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire and the 26-item pancreatic cancer module. End points were mean changes from baseline QoL scores, deterioration-free survival of QoL, and time to opioid use. An analysis of pain medication use was performed post hoc. Results: At baseline, 562 patients (median [IQR] age, 67 [31-90] years; 295 [52.5%] female), including 279 of 285 patients in the TTFields plus gemcitabine and nab-paclitaxel arm and 283 of 286 patients in the gemcitabine and nab-paclitaxel arm, completed the EORTC QLQ-C30 questionnaire. Global health status was stable during the 26-month follow-up in both study arms. Digestive symptoms, pain, and pancreatic pain were improved from 2 months after treatment initiation throughout treatment and follow-up in the TTFields plus gemcitabine and nab-paclitaxel arm. TTFields plus gemcitabine and nab-paclitaxel was associated with longer deterioration-free survival for global health status than gemcitabine and nab-paclitaxel alone (median [IQR], 7.1 [3.5-14.8] vs 5.7 [2.3-11.5] months; hazard ratio [HR], 0.77; 95% CI, 0.61-0.97; P = .02). Longer deterioration-free survival was also observed for most items on the digestive symptoms scales (indigestion and altered bowel habit were similar between the 2 arms). Median (IQR) deterioration-free survival was significantly longer with TTFields plus gemcitabine and nab-paclitaxel for pain (10.1 [4.0-20.9] vs 7.4 [3.5-14.5] months; HR, 0.70; 95% CI, 0.54-0.89; P = .003) and pancreatic pain (14.7 [6.2-46.2] vs 10.2 [5.6-18.2] months; HR, 0.69; 95% CI, 0.52-0.90; P = .006) as was median time to opioid use in the modified intention-to-treat population (9.3 [3.9-18.6] vs 6.7 [1.1-16.3] months; HR, 0.72; 95% CI, 0.55-0.93; P = .01). Conclusions and Relevance: This secondary analysis of a randomized clinical trial found that TTFields therapy with gemcitabine and nab-paclitaxel improved QoL and provided clinically meaningful benefits in pain outcomes compared with gemcitabine and nab-paclitaxel alone. This study's results suggest that TTFields therapy with gemicitabine and nab-paclitaxel is practice-changing for patients with unresectable LA-PAC. Trial Registration: ClinicalTrials.gov Identifier: NCT03377491.

Authors

Institutions

Publication Details

Journal
JAMA Network Open
Published
2026-11-13
DOI
https://doi.org/10.1001/jamanetworkopen.2026.41241
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Tumor Treating Fields and Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma: A Secondary Analysis of a Randomized Clinical Trial

Andrew Hendifar, Higinia Rosa Cardenes, Arsen Osipov, Anup Kasi et al.
3 links
JAMA Network Open
Pancreatic and Hepatic Oncology Research
article

Tumor Treating Fields and Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma: A Secondary Analysis of a Randomized Clinical Trial

Andrew Hendifar, Higinia Rosa Cardenes, Arsen Osipov, Anup Kasi, Daniel Rausch, Anand Mahadevan, Ashiq Masood, Douglas Orr, Joanna Amy Kolodney, Kynan Feeney, Bohuslav Melichar, Jason Tache, Mohit Narang, Mark D. Kochenderfer, Samer Shihabi, Joseph Stilwill, Sumana Nagireddy, Panagiotis Valilis, Trevor M. Feinstein, Judith D. Sears, ANTHONY SHIELDS, Vincent J. Picozzi, Timothy K. Huyck, Makoto Ueno, Lucjan Stanislaw Wyrwicz, Hassan A. Hatoum, Hani M. Babiker, Henrik Illum, Christelle de la Fouchardière, Thomas Theodor Werner Seufferlein, Benjamin L. Schlechter, Emil Lou, Tomislav Dragovich, Andrea J. Bullock, Philip Philip, Deepti Behl, Scott McKenney, Teresa Mercade Macarulla, Peter J. Van Veldhuizen, Kannan Thanikachalam, Maen Abdelrahim, Nadia N. Ramdin, Eric Van Cutsem, Cusnir Mike, Jaswinder Singh, Yixing Jiang, Warren S. Brenner, Carlos Becerra, Ali Tasneem, Sreenivasa Rao Chandana, Sudhir Manda, P. A. Philip, Nicholas Alfred Blondin, Venu Gopal Bathini, Alexander Rosemurgy, Anna Niewiaroska, Hao Chunyi, WooJin Lee, Jin Gang, Audrey Kam, Robert Marsh, James Reeves, Sharona Ross, Joshua Raff, Jennifer De Los Santos, WILLIAM SMALL, Marisa Hill, Francis Arena, Marc Uemura, Paul DeRose, Javier Gallego, David Spigel, Rachna Shroff, David Einspahr, Mary Peters, Herbert Newton, Michael Anderson, Garrett Green, Sunil Gandhi, John Hamm, Andrew Coveler, Lucas Wong, Joseph Ye, Steven DiBiase, Ajit Maniam, Donald Richards, Joanna Bendell, Richard Siegel, PANOVA-3 study investigators, Marc Matrana, James Wang, Fadi Braiteh, John Russell
article en

Abstract

Importance: The PANOVA-3 trial demonstrated the survival benefit and tolerability of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel, but understanding the impact of TTFields therapy on quality of life (QoL) and pain is important for clinical decision-making. Objective: To analyze the impact of TTFields therapy concomitant with gemcitabine and nab-paclitaxel on QoL and pain outcomes using prospective data from PANOVA-3. Design, Setting, and Participants: This is a prespecified secondary analysis of PANOVA-3, which was a global, open-label, multicenter, phase 3 randomized clinical trial in adult patients with previously untreated locally advanced unresectable pancreatic adenocarcinoma (LA-PAC). A total of 571 patients were randomized between May 1, 2018, and March 31, 2023, with follow-up completed October 31, 2024. Data analysis was performed from November 2024 to May 2025. Intervention: Patients were randomized 1:1 to receive either TTFields therapy (150 kHz) with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. Nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) were administered intravenously on days 1, 8, and 15 of 28-day cycles. Duration of follow-up was 18 months. Main Outcomes and Measures: QoL was measured using the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire and the 26-item pancreatic cancer module. End points were mean changes from baseline QoL scores, deterioration-free survival of QoL, and time to opioid use. An analysis of pain medication use was performed post hoc. Results: At baseline, 562 patients (median [IQR] age, 67 [31-90] years; 295 [52.5%] female), including 279 of 285 patients in the TTFields plus gemcitabine and nab-paclitaxel arm and 283 of 286 patients in the gemcitabine and nab-paclitaxel arm, completed the EORTC QLQ-C30 questionnaire. Global health status was stable during the 26-month follow-up in both study arms. Digestive symptoms, pain, and pancreatic pain were improved from 2 months after treatment initiation throughout treatment and follow-up in the TTFields plus gemcitabine and nab-paclitaxel arm. TTFields plus gemcitabine and nab-paclitaxel was associated with longer deterioration-free survival for global health status than gemcitabine and nab-paclitaxel alone (median [IQR], 7.1 [3.5-14.8] vs 5.7 [2.3-11.5] months; hazard ratio [HR], 0.77; 95% CI, 0.61-0.97; P = .02). Longer deterioration-free survival was also observed for most items on the digestive symptoms scales (indigestion and altered bowel habit were similar between the 2 arms). Median (IQR) deterioration-free survival was significantly longer with TTFields plus gemcitabine and nab-paclitaxel for pain (10.1 [4.0-20.9] vs 7.4 [3.5-14.5] months; HR, 0.70; 95% CI, 0.54-0.89; P = .003) and pancreatic pain (14.7 [6.2-46.2] vs 10.2 [5.6-18.2] months; HR, 0.69; 95% CI, 0.52-0.90; P = .006) as was median time to opioid use in the modified intention-to-treat population (9.3 [3.9-18.6] vs 6.7 [1.1-16.3] months; HR, 0.72; 95% CI, 0.55-0.93; P = .01). Conclusions and Relevance: This secondary analysis of a randomized clinical trial found that TTFields therapy with gemcitabine and nab-paclitaxel improved QoL and provided clinically meaningful benefits in pain outcomes compared with gemcitabine and nab-paclitaxel alone. This study's results suggest that TTFields therapy with gemicitabine and nab-paclitaxel is practice-changing for patients with unresectable LA-PAC. Trial Registration: ClinicalTrials.gov Identifier: NCT03377491.

JAMA Network OpenVol. 9(11)
Cedars-Sinai Medical Center (US), Beth Israel Deaconess Medical Center (US), Virginia Mason Medical Center (US), Harvard University (US), Wayne State University (US), Henry Ford Hospital (US), St John of God Murdoch Hospital (AU), Peking University Cancer Hospital (CN), Centre Léon Bérard (FR), University Hospital Olomouc (CZ), Hospital Clínic de Barcelona (ES), Changhai Hospital (CN), Hospital General Universitario de Elche (ES), National Cancer Center (KR), University of Kansas Medical Center (US), Mayo Clinic in Florida (US), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), University Hospital Ulm (DE), Kanagawa Cancer Center (JP), Baptist MD Anderson Cancer Center (US), Palacký University Olomouc (CZ), KU Leuven (BE)
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon